Birth Characteristics Among Children Diagnosed with Neurofibromatosis Type 1 and Tuberous Sclerosis - 15/11/21
, Hanna Mogensen, MSc 1, Christina-Evmorfia Kampitsi, MSc 1, Ann Nordgren, MD, PhD 2, 3, 4, Maria Feychting, PhD 1Abstract |
Objective |
To evaluate whether children with neurofibromatosis type 1 (NF1) and tuberous sclerosis have different birth characteristics compared with the general population.
Study design |
We identified all individuals born in Sweden between 1973 and 2014 from the nationwide Medical Birth Register for whom information on both biological parents was available (n = 4 242 122). Individuals with NF1 and individuals with tuberous sclerosis were identified using data from Swedish population-based health data registers. Using logistic regression models, we assessed the associations between these 2 neurocutaneous syndromes and birth characteristics in a cohort that included 1804 subjects with NF1 and 450 with tuberous sclerosis.
Results |
Children with NF1 and tuberous sclerosis were significantly more likely to be born preterm and via cesarean delivery. In addition, children with NF1 were also more likely to be born with other birth characteristics, such as short length, a large head circumference, and a low Apgar score. Moreover, children with NF1 had an increased odds of being born with a high birth weight or large for gestational age (OR, 1.61; 95% CI, 1.42-1.82 and OR, 1.82; 95% CI, 1.60-2.06, respectively).
Conclusion |
Children with NF1 and tuberous sclerosis differ from the general population in terms of several birth characteristics, with the strongest associations observed for high birth weight and large for gestational age in individuals with NF1.
Le texte complet de cet article est disponible en PDF.Keywords : neurofibromatosis type 1, tuberous sclerosis, birth weight, preterm birth, birth length, head circumference
Abbreviations : ICD, LGA, MBR, NF1, NF2, PIN
Plan
| Supported by grants from the Swedish Cancer Society (2015/724, to M.F.), the Swedish Research Council (2017-02913, to M.F.), the Swedish Childhood Cancer Foundation (PR2019-0027, to A.N.), the Berth von Kantzow Foundation (PR2018, to A.N.), the Hållsten Research Foundation (PR2019, to A.N.), and the Cancer Research Funds of Radiumhemmet (R01 141312, to A.N.). The funders/sponsors did not participate in the work. The authors declare no conflicts of interest. |
Vol 239
P. 200 - décembre 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
